



## ANNEX 1

### Response document for MHRA public consultation on the proposal to make Acnecide Face Gel and Acnecide Face Wash available from general sales outlets without prescription

Ref: ARM 98

---

#### Your details

Name: [REDACTED]

Position (if applicable): Policy Manager

Organisation (if applicable): National Pharmacy Association

Email: [REDACTED]

**1. Do you consider that Acnecide Face Gel and Acnecide Face Wash should be available as General Sale List (GSL) medicines?**

Yes ☐      No ☒      Not sure ☐

Please provide any comments or evidence to support your response:

Community Pharmacists are the most accessible clinicians on the high street, and they are increasingly available over extended opening hours to provide advice on medications as well on preventing ill-health, without the need of an appointment.

The provision of Acnecide Face Gel ought to continue to be through the pharmacy as a P medicine. One of the main side-effects of this product is skin reactions including very commonly dryness, redness, peeling and a burning sensation. The advice is that if "excessive irritation occurs, the patient is advised to reduce the usage of this product". Community pharmacists are well positioned to provide the advice and support to the customer, including side-effects, potential interactions and usage advice.

Furthermore, evidence suggest that Acne can have profound social and psychological effects. As a clinician the community pharmacist would be able to provide support and signposting as and when required, which would in some way mitigate against any anxiety and stress that this condition may cause.

Hence, the NPA suggests that this product should remain at the P classification i.e. only sold through community pharmacies.

**2. Do you have any specific comments on the leaflets or the labels provided in the public reclassification report for Acnecide Face Gel and Acnecide Face Wash?**

**3. Do you have any other comments on the reclassification?**

Furthermore, evidence suggest that Acne can have profound social and psychological effects. As a clinician, the community pharmacist would be able to provide support and signposting as and when required, which would in some way mitigate against any anxiety and stress that this condition may cause.

Hence, the NPA suggests that this product should remain at the P classification i.e. only sold through community pharmacies.

**4. The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes ☐

Partially\* ☐

No ☒

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information, we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gov.uk](mailto:reclassification@mhra.gov.uk)) to arrive by **30 May 2019**. Contributions received after that date cannot be included in the exercise.